Loading stock data…
$1.49-0.06 (-4.18%)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
InflaRx N.V. in the Healthcare sector is trading at $1.49 with a market capitalization of $298M. Wall Street consensus targets $7.65 (9 analysts), implying a +415.4% move over the next 12 months. The stock is currently 50% below its 52-week high of $2.95, remaining 7.8% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↑ | -$33,931↓ | $23,830↓ | $39,432 |
| Gross Profit | $0 | $0↑ | -$4.89M↓ | $23,497↑ | -$2.36M |
| Operating Income | -$7.00M↑ | -$7.21M↑ | -$12.86M↓ | -$9.48M↑ | -$12.94M |
| Net Income | -$10.65M↓ | -$5.59M↑ | -$10.64M↑ | -$12.26M↑ | -$14.42M |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory dis...